Hepatitis C management by addiction medicine physicians: Results from a national survey

Journal of Substance Abuse Treatment

Volumn 33, Issue 1, 2007, Pages 99-105

  Litwin, Alain H ^a   Kunins, Hillary V ^a   Berg, Karina M ^a   Federman, Alex D ^b   Heavner, Karyn K ^c   Gourevitch, Marc N ^d   Arnsten, Julia H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c AIDS Institute   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction medicine; Chronic hepatitis C; Drug users; Hepatitis C virus; Substance abuse treatment physicians

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS A VACCINE; HEPATITIS B VACCINE; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY;

ANTIBODY SCREENING; ANTIVIRAL THERAPY; ARTICLE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG USE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; OUTCOME VARIABLE; PATIENT REFERRAL; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; VACCINATION; BLOOD; CLINICAL PRACTICE; COMORBIDITY; CROSS-SECTIONAL STUDY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MASS SCREENING; MEDICINE; MENTAL HEALTH SERVICE; MULTIMODALITY CANCER THERAPY; PRIMARY HEALTH CARE; SUBSTANCE ABUSE; UNITED STATES;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DELIVERY OF HEALTH CARE; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MASS SCREENING; MENTAL HEALTH SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; QUALITY ASSURANCE, HEALTH CARE; REFERRAL AND CONSULTATION; SPECIALTIES, MEDICAL; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 35248887678     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2006.12.001     Document Type: Article

References (35)

1. Alter M.J., and Moyer L.A. The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 18 Suppl 1 (1998) S6-S10
2. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States 1999 through 2002. Annals of Internal Medicine 144 (2006) 705-714
3. Backmund M., Meyer K., Von Zielonka M., and Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 34 (2001) 188-193
4. Best D., Noble A., Finch E., Gossop M., Sidwell C., and Strang J. Accuracy of perceptions of hepatitis B and C status: Cross-sectional investigation of opiate addicts in treatment. British Medical Journal 319 (1999) 290-291
5. Clark E.C., Yawn B.P., Galliher J.M., Temte J.L., and Hickner J. Hepatitis C identification and management by family physicians. Family Medicine 37 (2005) 644-649
6. Cournot M., Gilbert A., Castel F., Druart F., Imani K., Lauwers-Cances V., et al. Management of hepatitis C inactive drug users: Experience of an addiction care hepatology unit. Gastroenterologie Clinique et Biologique 28 (2004) 533-539
7. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B., et al. Treatment of chronic hepatitis C in injecting drug users: 5 Years' follow-up. European Addiction Research 8 (2002) 45-49
8. Davis G.L., and Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine 345 (2001) 215-217
9. Edlin BR. Five million Americans infected with the hepatitis C virus: A corrected estimate. Abstract, American Association for the Treatment of Liver Disease 2005, San Francisco, CA.
10. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users?. New England Journal of Medicine 345 (2001) 211-215
11. Everhart J.E., Stolar M., and Hoofnagle J.H. Management of hepatitis C: A national survey of gastroenterologists and hepatologists. Hepatology 26 3 Suppl 1 (1997) 78S-82S
12. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347 (2002) 975-982
13. Garfein R.S., Vlahov D., Galai N., Doherty M.C., and Nelson K.E. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health 86 (1996) 655-661
14. Gourevitch M.N., Hartel D., Selwyn P.A., Schoenbaum E.E., and Klein R.S. Effectiveness of isoniazid chemoprophylaxis in HIV-infected drug users at high risk for active tuberculosis. AIDS 319 (1999) 2069-2074
15. Hagan H., Latka M.H., Campbell J.V., Golub E.T., Garfein R.S., Thomas D.A., et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clinical Infectious Diseases 42 (2006) 669-672
16. Hagan H., Strauss S.M., Astone J.M., and Des Jarleis D.C. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clinical Infectious Diseases 40 (2005) S297-S303
17. Lauer G.M., and Walker B.D. Hepatitis C virus infection. New England Journal of Medicine 347 (2002) 975-982
18. Lorvick J., Kral A.H., Seal K., Gee L., and Edlin B.R. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. American Journal of Public Health 91 (2001) 46-47
19. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358 (2001) 958-965
20. Montano D., and Philip W. Cancer screening by primary care physicians: A comparison of rates obtained from physician self-report, patient survey and chart audit. American Journal of Public Health 85 (1995) 795-800
21. Murrill C.S., Weeks H., Castrucci B.C., Weinstock H.S., Bell B.P., Spruill C., et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health 92 (2002) 385-387
22. National Institutes of Health Consensus Development Conference Statement on the Management of Hepatitis C. Management of hepatitis C. Hepatology 36 (2002) S3-S20
23. Nicklin D.E., Schultz C., Bessinger C.M., and Wilson J.P. Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system. Journal of the American Board of Family Practice 12 (1999) 427-435
24. O'Connor P.G., Molde S., Henry S., Shockcor W.T., and Schottenfeld R.S. Human immunodeficiency virus infection in intravenous drug users: A model for primary care. American Journal of Medicine 93 (1992) 382-386
25. O'Connor P.G., Selwyn P.A., and Schottenfeld R.S. Medical care for injection drug users with human immunodeficiency virus infection. New England Journal of Medicine 331 (1994) 450-459
26. Selwyn P.A., Feingold A.R., Iezza A., Satyadeo M., Colley J., Torres R., et al. Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Annals of Internal Medicine 111 (1989) 761-763
27. Shehab T.M., Sonnad S.S., Jeffries M., Gunaratnum N., and Lok A.S.F. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 30 (1999) 794-800
28. Shehab T.M., Sonnad S.S., and Lok A.S.F. Management of hepatitis C patients by primary care physicians in the USA: Results of a national survey. Journal of Viral Hepatitis 8 (2001) 377-383
29. Sterling R.K., and Sulkowski M.S. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Seminars in Liver Disease 24 Suppl 2 (2004) 61-68
30. Strauss S.M., Falkin G.P., Vassilev Z., Des Jarleis D.C., and Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. Journal of Substance Abuse Treatment 22 (2002) 55-62
31. Sylvestre D.L., Litwin A.H., Clements B.J., and Gourevitch M.N. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment 29 (2005) 159-165
32. Thomas D.L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., et al. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 (1995) 212-220
33. Van Thiel D.H., Anantharaju A., and Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology 98 (2003) 2281-2288
34. Vassilev Z.P., Strauss S.M., Astone J.M., Friedmann P.D., and Des Jarleis D.C. Provision of on-site medical care to patients with hepatitis C in drug treatment units. Journal of Health Care for the Poor and Underserved 15 (2004) 663-671
35. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. New England Journal of Medicine 338 (1998) 286-290